Does Humana Cover ADHD Treatment in Delaware? A 2026 Guide

Last updated: July 23, 2026

Key Facts. Humana ADHD Coverage in Delaware (2026)

• Plan type: Humana offers Medicare Advantage (MAPD) plans in Delaware only. No commercial individual or employer-sponsored plans.
• PBM: Humana Pharmacy Solutions (HPS) administers Part D drug benefits.
• Governing framework: CMS 42 CFR Part 422. Not Delaware’s § 3343 state parity law, which is preempted by federal Medicare law for MAPD plans.
• All stimulants require prior authorization (PA) under HPS, including generic amphetamine salts and generic methylphenidate.
• Schedule II stimulants EPCS REQUIRED in Delaware. Prescribers must use an approved Electronic Prescribing for Controlled Substances system.
• Non-stimulants (atomoxetine/Strattera, viloxazine ER/Qelbree, guanfacine ER, clonidine ER) are non-scheduled and EPCS is inapplicable.
• Dual-eligible (Medicare + Medicaid) members may have different cost-sharing under Delaware’s Medicaid program; see disclaimer below.
• Federal appeal pathway: CMS redetermination → Maximus IRE 1-855-887-6668 → ALJ.
• Contacts: Humana 1-800-448-6262 / HPS 1-800-379-0092 / DE Insurance Commissioner 1-302-674-7300 (limited MAPD jurisdiction. See below).

Overview: Humana ADHD Coverage in Delaware

Humana’s presence in Delaware is limited to Medicare Advantage Prescription Drug (MAPD) plans. If you are a Delaware resident under 65 or covered by an employer-sponsored or ACA marketplace plan, Humana is not your insurer for this purpose. This guide is specifically for Delaware Medicare beneficiaries. And their families or caregivers. Who are enrolled in a Humana MAPD plan and want to understand how ADHD treatment may be covered.

ADHD affects adults of all ages, including Medicare beneficiaries, and effective treatment. Including stimulant and non-stimulant medications. May be covered under your Humana Medicare Advantage plan. Coverage terms, prior authorization requirements, and formulary placement vary by specific plan. Verify your benefits before booking.

Klarity Health connects Delaware residents with licensed providers who accept Humana Medicare Advantage and other major insurance plans. Our network of 2,000+ providers specializes in ADHD evaluation and treatment. Check if your plan may cover ADHD treatment through Klarity →

Medicare Advantage Only: What This Means for Delaware Residents

Humana exited most commercial markets in Delaware in recent years. As of 2026, Humana operates Medicare Advantage plans in Delaware. Plans that replace Original Medicare (Parts A and B) and typically include Part D prescription drug coverage through the Humana Pharmacy Solutions (HPS) PBM.

This distinction matters for several reasons:

• Eligibility: You must be 65 or older, or qualify for Medicare through disability or ESRD, to enroll in Humana MAPD in Delaware.
• Governing law: Your plan is governed by CMS regulations under 42 CFR Part 422, not Delaware’s state insurance statutes (see preemption section below).
• Drug coverage: ADHD medications are covered under Part D as managed by HPS, subject to the plan’s formulary, prior authorization policies, and tier placement.
• Out-of-pocket costs: Cost-sharing varies by plan tier and specific medication. Review your plan’s Evidence of Coverage (EOC) for exact copay/coinsurance amounts.

CMS 42 CFR Part 422: The Governing Framework for Humana MAPD

When you enroll in a Humana Medicare Advantage plan, the rules that govern your coverage come primarily from federal CMS regulations. Specifically 42 CFR Part 422 (Medicare Advantage organization requirements) and 42 CFR Part 423 (Part D prescription drug program).

This federal framework requires Humana to:

• Cover all medically necessary services that Original Medicare covers (and typically more)
• Apply non-discriminatory formulary design and utilization management
• Provide access to mental health and substance use disorder treatment, including ADHD medications, under CMS coverage standards
• Follow CMS formulary requirements, including coverage of drugs in certain protected categories
• Adhere to CMS standards for prior authorization, appeals, and grievances

CMS oversight means that if Humana’s ADHD coverage practices violate federal Medicare standards, you can escalate complaints directly to CMS. Not just to Humana.

HPS Formulary: ADHD Medications Under Humana Delaware Plans

Humana Pharmacy Solutions (HPS) manages the Part D drug formulary for Humana MAPD plans. The following table reflects typical HPS formulary placement for common ADHD medications; your specific plan’s formulary may vary. Always confirm with HPS at 1-800-379-0092 or via your plan’s online formulary tool.

Formulary tier and PA requirements are subject to change. Confirm with HPS before filling your prescription.

All Stimulants Require Prior Authorization Under HPS

A defining feature of Humana’s ADHD coverage in Delaware is that all stimulant ADHD medications require prior authorization under the HPS formulary. Including generic first-line options such as generic amphetamine salts and generic methylphenidate. This is a notable difference from some other Delaware insurers where generic stimulants at Tier 1. 2 may be dispensed without PA.

PA requirements for stimulants under HPS typically include:

1. Diagnosis confirmation: Documentation of ADHD diagnosis by a licensed provider (MD, DO, NP, PA, or psychiatrist)
2. Medical necessity: Clinical records supporting that stimulant treatment is appropriate for the member’s age, comorbidities, and clinical presentation
3. Medicare eligibility: Confirmation that the member is a Medicare beneficiary and the drug is a Part D-eligible medication
4. Formulary compliance: The prescribed drug must appear on the HPS Part D formulary for the member’s specific plan
5. Quantity limits: PA may include quantity limits per CMS utilization management standards

Tip for providers: If an initial PA is denied, request a peer-to-peer (P2P) review with a Humana/HPS medical reviewer. P2P reviews often result in reconsideration when the prescribing provider can speak directly to the clinical necessity and prior treatment history.

Delaware EPCS Requirements for Schedule II Stimulants

Delaware requires Electronic Prescribing for Controlled Substances (EPCS) for Schedule II medications. Under Delaware Administrative Code Title 24, § 1700 (Delaware Uniform Controlled Substances Act implementing regulations), all Schedule II prescriptions. Including amphetamine salts and methylphenidate. Must be transmitted electronically by a prescriber using a DEA-compliant EPCS system.

For telehealth providers: EPCS is a prescriber-level requirement, not an insurer restriction. Klarity’s licensed providers are equipped to transmit Schedule II EPCS prescriptions in Delaware where clinically appropriate and legally permitted. Non-stimulant ADHD medications have no EPCS barrier and can be prescribed through standard telehealth visits.

Delaware § 3343 and Federal MA Preemption

Delaware’s mental health parity law. Del. Code Ann. tit. 18, § 3343. Is aligned with the federal Mental Health Parity and Addiction Equity Act (MHPAEA) and requires insurers to cover mental health conditions (including ADHD) under the same terms and limitations as medical/surgical conditions. Under § 3343, insurers may not impose more restrictive PA requirements, quantity limits, or step therapy for ADHD treatment than they apply to comparable medical/surgical conditions.

However, for Humana MAPD plans, § 3343 is preempted by federal Medicare law. Medicare Advantage plans are federal programs regulated under 42 CFR Part 422. Federal law generally preempts state insurance regulations for MAPD plans, meaning Delaware’s DOI cannot compel Humana to comply with § 3343 in the same way it can enforce state law against commercial insurers.

This does not mean ADHD parity protections are absent for Humana MAPD members. CMS requires mental health parity compliance under its own MAPD standards. But the enforcement mechanism is federal, not state:

• Complaints about ADHD coverage practices go to CMS, not primarily to the DE DOI
• Appeals follow the federal Medicare appeal process, not Delaware’s state external review process
• The DE DOI (1-302-674-7300) can accept complaints but has limited enforcement authority over MAPD plans

Medicaid and Dual-Eligible Members

Some Delaware Medicare beneficiaries are also enrolled in Delaware Medicaid (Diamond State Health Plan or DSHP), making them dual-eligible. For dual-eligible members enrolled in a Humana MAPD plan:

• ADHD medication cost-sharing may be reduced or eliminated through Medicare Savings Programs or full Medicaid dual coverage
• The Low Income Subsidy (LIS/Extra Help) program reduces Part D premiums and cost-sharing for qualifying beneficiaries
• Some dual-eligible members are enrolled in Dual Eligible Special Needs Plans (D-SNPs), which coordinate between Medicare and Medicaid more tightly
• For Medicaid-specific ADHD medication questions (non-MAPD members), contact Delaware Division of Medicaid and Medical Assistance (DMMA): 1-800-372-2022

This guide covers Humana Medicare Advantage (MAPD) plans only. Medicaid-only or commercial plan coverage is different. Verify which program governs your specific coverage.

Prior Authorization Process: Step-by-Step

1. Confirm plan enrollment: Verify your specific Humana MAPD plan name and group/member ID. Different MAPD plans may have different formulary tiers for the same medication.
2. Check the HPS formulary: Use the Humana online formulary tool or call HPS at 1-800-379-0092 to confirm your medication’s tier, PA status, and quantity limits.
3. Provider submits PA request: Your prescribing provider (or their office) submits a PA request to HPS with clinical documentation: ADHD diagnosis, prior treatment history, and medical necessity rationale.
4. HPS review timeline: Standard PA decisions are typically made within 72 hours; urgent/expedited requests within 24 hours under CMS standards.
5. Response and next steps: If approved, your pharmacy can fill the prescription. If denied, you receive a Notice of Action with the reason for denial and instructions for appeal.

Appeal Process: Federal Medicare Pathway

If your ADHD medication claim or PA is denied by Humana/HPS, the federal Medicare appeal process applies. Note that Delaware’s state external review process does not apply to MAPD plans.

1. Level 1. Humana Redetermination: Request a redetermination from Humana within 60 days of the denial notice. Humana must respond within 60 days (standard) or 72 hours (expedited for urgent medical need).
2. Level 2. Qualified Independent Contractor (QIC) / Maximus IRE: If Humana upholds the denial, your case is automatically forwarded to the independent Maximus Federal Services (Maximus IRE) at 1-855-887-6668. Maximus will review independently of Humana.
3. Level 3. ALJ Hearing: If Maximus upholds the denial and the amount in controversy meets the threshold ($180+ in 2026), you may request an Administrative Law Judge (ALJ) hearing through the Office of Medicare Hearings and Appeals (OMHA).
4. Level 4. Medicare Appeals Council: Further review by the Medicare Appeals Council (MAC/DAB).
5. Level 5. Federal District Court: Final review in federal district court if the amount in controversy meets the threshold.

CMS complaint line: 1-800-633-4227 (1-800-MEDICARE). You may also file a complaint at medicare.gov or through your State Health Insurance Assistance Program (SHIP): Delaware SHIP (DMAB) 1-800-336-9500.

Telehealth ADHD Treatment with Humana in Delaware

Humana Medicare Advantage plans typically cover telehealth mental health services, including ADHD evaluation and medication management, in accordance with expanded CMS telehealth rules. Key considerations:

• Non-stimulant ADHD medications (atomoxetine, viloxazine ER, guanfacine ER, clonidine ER) can generally be prescribed via telehealth with no EPCS barrier. These are non-scheduled medications.
• Stimulant ADHD medications (amphetamine salts, methylphenidate) are Schedule II and require EPCS regardless of whether the visit is in-person or telehealth. Klarity’s telehealth providers use DEA-compliant EPCS systems for Delaware patients.
• Ryan Haight Act compliance: Federal telehealth prescribing rules for Schedule II controlled substances require a qualifying patient-provider relationship. Klarity providers conduct thorough evaluations to meet these standards.
• PA must still be obtained from HPS before dispensing, whether the visit is telehealth or in-person.

Humana vs. Other Delaware Insurers: ADHD Coverage Comparison

Coverage details are subject to change. Verify current PA requirements with your specific insurer and plan before initiating treatment.

Verify Your Humana ADHD Coverage: 5-Step Checklist

1. Confirm plan type: Verify you are enrolled in a Humana Medicare Advantage (MAPD) plan, not a standalone Part D plan or commercial plan.
2. Check the HPS formulary: Call HPS at 1-800-379-0092 or use the Humana online formulary tool to confirm your specific ADHD medication’s tier, PA status, and quantity limits.
3. Request PA before filling: Work with your prescribing provider to submit a PA request to HPS before attempting to fill stimulant prescriptions.
4. Confirm EPCS readiness: If you need a Schedule II stimulant, verify your provider uses a DEA-compliant EPCS system and is registered to e-prescribe in Delaware.
5. Know your appeal rights: If denied, you have federal Medicare appeal rights through Humana redetermination → Maximus IRE → ALJ. Keep all denial notices and appeal deadlines.

Get Started with ADHD Treatment

Klarity Health’s network of 2,000+ licensed providers specializes in ADHD evaluation and treatment. We work with Humana Medicare Advantage and other major Delaware insurance plans. Our providers use DEA-compliant EPCS systems for Schedule II prescriptions in Delaware. Check if your plan may cover ADHD treatment through Klarity →

Frequently Asked Questions

Does Humana cover ADHD medication for Medicare Advantage members in Delaware?

Humana Medicare Advantage plans in Delaware typically include Part D prescription drug coverage through HPS, which may cover ADHD medications subject to formulary placement, prior authorization, and quantity limits. Coverage varies by specific plan. Verify your benefits with HPS at 1-800-379-0092 before booking.

Why do all stimulants require PA under Humana HPS?

HPS applies universal PA requirements to stimulant ADHD medications as a utilization management measure. This is consistent with CMS Part D utilization management standards and applies to generic and brand stimulants alike. Your provider can submit a PA request with clinical documentation supporting medical necessity.

Can I get ADHD treatment via telehealth with Humana in Delaware?

Yes. Humana MAPD plans typically cover telehealth mental health services under expanded CMS telehealth rules. Non-stimulant ADHD medications have no EPCS barrier for telehealth prescribing. Stimulant medications require EPCS regardless of visit type. Klarity’s providers use compliant systems. PA must be obtained before dispensing in all cases.

Does Delaware’s § 3343 mental health parity law apply to my Humana MAPD plan?

Delaware’s § 3343 is preempted by federal Medicare law for MAPD plans. Your Humana MAPD plan is governed by CMS 42 CFR Part 422, not § 3343. Mental health parity protections still apply under CMS standards, but enforcement goes through federal channels (CMS, Maximus IRE, ALJ) rather than the Delaware DOI’s state external review process.

What if my ADHD medication is denied by Humana HPS?

You have federal Medicare appeal rights: (1) Request a Humana redetermination within 60 days; (2) If denied, your case goes to Maximus IRE (1-855-887-6668) for independent review; (3) If still denied and the amount meets the threshold, request an ALJ hearing. Contact CMS at 1-800-633-4227 to file a complaint or get guidance on your rights.

Is Humana available for non-Medicare Delaware residents?

As of 2026, Humana does not offer commercial individual or employer-sponsored health plans in Delaware. Humana’s Delaware presence is limited to Medicare Advantage plans. Delaware residents under 65 or on employer-sponsored coverage should look to UHC, Highmark BCBS DE, Aetna, or Cigna for commercial ADHD coverage options.

Key Contacts

• Humana Member Services: 1-800-448-6262
• Humana Pharmacy Solutions (HPS): 1-800-379-0092
• Delaware Insurance Commissioner: 1-302-674-7300 (note: limited jurisdiction over MAPD plans)
• CMS / Medicare: 1-800-633-4227 (1-800-MEDICARE)
• Maximus IRE (Medicare appeals): 1-855-887-6668
• Delaware SHIP (Medicare counseling): 1-800-336-9500
• Delaware Medicaid (DMMA): 1-800-372-2022
• Klarity Health: helloklarity.com/service/adhd-treatment

Disclaimer: Coverage terms, formulary placement, PA requirements, and cost-sharing amounts vary by specific Humana Medicare Advantage plan and are subject to change. This guide reflects general 2026 information and is not a guarantee of coverage. Always verify your specific plan benefits with Humana (1-800-448-6262) or HPS (1-800-379-0092) before initiating treatment. Klarity Health providers are not affiliated with Humana or HPS. This content is for informational purposes only and does not constitute medical or legal advice.